THE USE OF COMPOSITIONS COMPRISING CARNOSIC ACID AND TWO OR MORE CAROTENOIDS IN THE TREATMENT OF INFLAMMATION

The present invention provides use of a combination of carnosic acid and two or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene for the treatment of inflammation in a mammalian subject. Each of the carnosic acid and carotenoids may be for administration in a daily amount in the range of 1 to 5 mg. In some embodiments, the carnosic acid and carotenoids are present in the following weight ratio range for lycopene:lutein:beta-carotene:carnosic acid of 0.1-1.0:0.1-1.0:0.1-1.0:0.1-1Ø In some embodiments, the mammalian subject has a condition selected from the group consisting of rheumatoid arthritis, adult respiratory distress syndrome (ARDS), asthma, rhinitis, idiopathic pulmonary fibrosis, peritonitis, cardiovascular inflammation, myocardial ischemia, reperfusion injury, atherosclerosis, sepsis, trauma, diabetes type II, retinopathy, psoriasis, gastrointestinal inflammation, cirrhosis, peritonitis and inflammatory bowel disease, and neurodegenerative diseases. La présente invention concerne une composition thérapeutique comprenant un ou plusieurs polyphénols et deux caroténoïdes ou davantage, choisis dans le groupe constitué de la lutéine, du lycopène et du bêta-carotène. L'invention concerne également des procédés permettant d'inhiber ou de réduire la production d'ions superoxyde, de NO, de TNF-alpha et/ou de PGE2 chez un sujet mammifère, procédés comprenant l'administration audit sujet de la composition thérapeutique susmentionnée.